MedPath

Overexpression of CXCR4, CXCL12 and CXCR7 as a therapeutic approach to restore sensitivity to novel agents in multiple myeloma.

Conditions
C90.0
Multiple myeloma
Registration Number
DRKS00009348
Lead Sponsor
niklinik Freiburg
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
130
Inclusion Criteria

Patients with multiple myeloma.

Exclusion Criteria

none

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Since the interaction of malignant plasma cells with the bone marrow is fundamental for multiple myeloma pathogenesis, the aim of our study was to analyze the CXCL12/CXCR4-axis and to examine the efficacy of targeting CXCR4/CXCL12 mediated adhesion to the bone marrow including effects on adhesion molecules.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath